Endovascular superselective treatment of brain tumors: A new endovascular era? A quick review

Journal of NeuroInterventional Surgery

Volumn 7, Issue 3, 2015, Pages 222-224

  Peschillo, Simone ^a   Miscusi, Massimo ^b   Missori, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CETUXIMAB; CISPLATIN; METHOTREXATE; NIMUSTINE; PLATINUM DERIVATIVE; TEMOZOLOMIDE; VASCULOTROPIN; VINCRISTINE;

BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; CANCER GRADING; CANCER PROGNOSIS; ENDOVASCULAR SURGERY; GLIOBLASTOMA; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIFE EXPECTANCY; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RETINOPATHY; REVIEW; ANIMAL; BRAIN NEOPLASMS; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; ENDOVASCULAR PROCEDURES; GLIOBLASTOMA; HUMANS; INFUSIONS, INTRA-ARTERIAL; TREATMENT OUTCOME;

EID: 84922714405     PISSN: 17598478     EISSN: 17598486     Source Type: Journal    
DOI: 10.1136/neurintsurg-2013-011095     Document Type: Review

References (33)

1. Peschillo S, Delfini R. Endovascular neurosurgery in Europe and in Italy: what is in the future? World Neurosurg 2012;77:248-51.
2. French JD, West PM, Von Amerongen FK, et al. Effects of intracarotid administration of nitrogen mustard on normal brain and brain tumors. J Neurosurg 1952;9:378-89.
3. Newton HB. Intra-arterial chemotherapy of primary brain tumors. Curr Treat Options Oncol 2005;6:519-30.
4. Owens G, Javid R, Belmusto L, et al. Intra-arterial vincristine therapy of primary gliomas. Cancer 1965;18:756-60.
5. Neuwelt EA, Minna J, Frenkel E, et al. Osmotic blood-brain barrier opening to IgM monoclonal antibody in the rat. Am J Physiol 1986;250 (5 Pt 2):R875-83
6. Neuwelt EA, Dahlborg SA. Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases. J Neurooncol 1987;4:195-207.
7. Feun LG, Wallace S, Yung WK, et al. Phase-I trial of intracarotid BCNu and cisplatin in patients with malignant intracerebral tumors. Cancer Drug Deliv 1984;1:239-45.
8. Safdari H, Mompeon B, Dubois JB, et al. Intra-arterial 1, 3-bis (2-chloroethyl)-1-nitrosourea chemotherapy for the treatment of malignant gliomas of the brain: a preliminary report. Surg Neurol 1985;24:490-7.
9. Feun LG, Lee YY, Yung WK, et al. Phase II trial of intracarotid BCNu and cisplatin in primary malignant brain tumors. Cancer Drug Deliv 1986;3:147-56.
10. Tonn JC, Roosen K, Schachenmayr W. Brain necroses after intraarterial chemotherapy and irradiation of malignant gliomas-a complication of both ACNu and BCNu? J Neurooncol 1991;11:241-2.
11. Shapiro WR, Green SB, Burger PC, et al. A randomized comparison of intra-arterial versus intravenous BCNu, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992;76:772-81.
12. Chow KL, Gobin YP, Cloughesy T, et al. Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. AJNR Am J Neuroradiol 2000;21:471-8.
13. Follezou JY, Fauchon F, Chiras J. Intraarterial infusion of carboplatin in the treatment of malignant gliomas: a phase II study. Neoplasma 1989;36:349-52.
14. Riina HA, Knopman J, Greenfield JP, et al. Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma. A technical note. Interv Neuroradiol 2010;16:71-6.
15. Peruzzi P, Chiocca EA. Bringing the endovascular neurosurgeon into the neuro-oncology treatment team. World Neurosurg 2012;77:59-61.
16. Qureshi AI, Suri MF, Khan J, et al. Superselective intra-arterial carboplatin for treatment of intracranial neoplasms: experience in 100 procedures. J Neurooncol 2001;51:151-8.
17. De Groot JF, Yung WK. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 2008;14:279-85.
18. Burkhardt JK, Riina H, Shin BJ, et al. Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. World Neurosurg 2012;77:130-4.
19. Rajappa P, Krass J, Riina HA, et al. Super-selective basilar artery infusion of bevacizumab and cetuximab for multiply recurrent pediatric ependymoma. Interv Neuroradiol 2011;17:459-65.
20. Shin BJ, Burkhardt JK, Riina HA, et al. Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series. Neurosurg Clin N Am 2012;23:323-9.
21. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40.
22. Sathornsumetee S, Rich JN. Antiangiogenic therapy in malignant glioma: promise and challenge. Curr Pharm Des 2007;13:3545-58.
23. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-9.
24. Cloughesy TF. A phase II, randomized, noncomparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS 6) in recurrent, treatment-refractory glioblastoma (GBM) (abstract 2010b). J Clin Oncol 2008;26(Suppl).
25. Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolamide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008;71:1372-80.
26. Pope WB, Lai A, Nghiemphu P, et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006;66:1258-60.
27. Gobin YP, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol 2011;129:732-7.
28. Gobin YP, Cloughesy TF, Chow KL, et al. Intraarterial chemotherapy for brain tumors by using a spatial dose fractionation algorithm and pulsatile delivery. Radiology 2001;218:724-32.
29. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
30. Riina HA, Fraser JF, Fralin S, et al. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. J Exp Ther Oncol 2009;8:145-50.
31. Boockvar JA, Tsiouris AJ, Hofstetter CP, et al. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood brain barrier disruption for recurrent malignant glioma. J Neurosurg 2011;114:624-32.
32. Jeon JY, Kovanlikaya I, Boockvar JA, et al. Metabolic response of glioblastoma to superselective intra-arterial cerebral infusion of bevacizumab: a proton MR spectroscopic imaging study. AJNR Am J Neuroradiol 2012;33:2095-102.
33. Burkhardt JK, Riina HA, Shin BJ, et al. Intra-arterial chemotherapy for malignant gliomas: a critical analysis. Interv Neuroradiol 2011;17:286-95.